Zevra Therapeutics Past Earnings Performance
Past criteria checks 0/6
Key information
-5.5%
Earnings growth rate
69.4%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 15.1% |
Return on equity | -101.3% |
Net Margin | -178.5% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate
May 26Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Zevra Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 28 | -49 | 38 | 43 |
31 Dec 23 | 27 | -46 | 35 | 39 |
30 Sep 23 | 17 | -27 | 25 | 34 |
30 Jun 23 | 17 | -19 | 24 | 27 |
31 Mar 23 | 9 | -38 | 20 | 25 |
31 Dec 22 | 10 | -27 | 16 | 19 |
30 Sep 22 | 11 | -35 | 13 | 16 |
30 Jun 22 | 10 | -30 | 11 | 12 |
31 Mar 22 | 20 | -17 | 10 | 10 |
31 Dec 21 | 29 | -63 | 9 | 10 |
30 Sep 21 | 28 | -65 | 9 | 10 |
30 Jun 21 | 28 | -66 | 9 | 9 |
31 Mar 21 | 23 | -55 | 8 | 8 |
31 Dec 20 | 13 | -13 | 8 | 8 |
30 Sep 20 | 12 | -14 | 7 | 8 |
30 Jun 20 | 22 | -8 | 10 | 10 |
31 Mar 20 | 15 | -18 | 11 | 12 |
31 Dec 19 | 13 | -25 | 11 | 19 |
30 Sep 19 | 11 | -24 | 13 | 23 |
30 Jun 19 | 0 | -42 | 12 | 32 |
31 Mar 19 | 0 | -43 | 13 | 38 |
31 Dec 18 | 0 | -56 | 13 | 41 |
30 Sep 18 | 0 | -62 | 13 | 41 |
30 Jun 18 | 0 | -57 | 13 | 33 |
31 Mar 18 | 0 | -53 | 13 | 28 |
31 Dec 17 | 0 | -43 | 13 | 20 |
30 Sep 17 | 0 | -43 | 13 | 23 |
30 Jun 17 | 0 | -45 | 13 | 21 |
31 Mar 17 | 0 | -30 | 14 | 21 |
31 Dec 16 | 0 | -17 | 14 | 20 |
30 Sep 16 | 0 | -16 | 14 | 17 |
30 Jun 16 | 0 | -13 | 13 | 17 |
31 Mar 16 | 0 | -52 | 12 | 15 |
31 Dec 15 | 0 | -55 | 9 | 14 |
30 Sep 15 | 0 | -57 | 8 | 15 |
30 Jun 15 | 0 | -55 | 7 | 14 |
31 Mar 15 | 0 | -29 | 5 | 13 |
31 Dec 14 | 0 | -24 | 5 | 12 |
30 Sep 14 | 0 | -14 | 3 | 7 |
Growing Profit Margin: ZVRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZVRA is unprofitable, and losses have increased over the past 5 years at a rate of 5.5% per year.